Abstract:Hypoxia imaging agents can play an important role in the tumor treatment by avoiding the worse effect of radiotherapy and chemotherapy due to the tumor hypoxia. Due to the small size and easy coordination, tricarbonyl technetium-99m can be used to label a wide range of imaging agents. In this work, the tricarbonyl Tc-99m labeled small-sized hypoxia imaging agents containing 2-nitroimidazoles were prepared, which have different carbon chain lengths between cyclopentadienyl and 2-nitroimidazole, and which have one or two 2-nitroimidazole groups. The results of S180 cell experiment and biodistribution indicated that these molecules have different hypoxic selectivity. When contains one 2-nitroimidazole, as the carbon chain lengthens, which means the molecular volume becomes larger, hypoxia cellular uptake and selectivity decrease in S180 cell uptake experiment. In biodistribution study in mice bearing S180 tumor, Tc-2 (1-cyclopentadienyl-5-(2-nitro-1H-imidazol-1-yl)-pentan-1-one tricarbonyl Tc-99m complex), which has intermediate carbon chain, is better due to the more complex factors. Its tumor/blood (T/B) ratio is 3.56 & PLUSMN; 0.25, tumor/muscle(T/M) ratio is 1.73 & PLUSMN; 0.29 and tumor uptake is 2.23 & PLUSMN; 0.24%ID/g at 2 h. Comparing to other tricarbonyl technetium complexes containing one 2-nitroimidazole, the complexes in this work have an advantage in tumor/blood ratio and tumor uptake. This suggests that the small-volume cyclopentadienyl may have an advantage when used as a ligand. When contains two 2nitroimidazole groups, the complex, 1-cyclopentadienyl-5-di(2-(2-nitro-1H-imidazol-1-yl)ethyl)amino-pentan1-one tricarbonyl Tc-99m complex (Tc-4), has the better results in the cell experiment than those which contain one 2-nitroimidazole group. Thus the hypoxia imaging agent contains two 2-nitroimidazole groups is more advantageous, but further modifications of Tc-4 are needed to improve its clearance rate in the blood, because the increased lipophilicity leads to a decrease in the T/B ratio of Tc-4. In conclusion, small volume hypoxia imaging agents with two 2-nitroimidazole groups may be the trend of development.

Kit formulation for preparation and biological evaluation of a novel 99m Tc-oxo complex with metronidazole xanthate for imaging tumor hypoxia

Synthesis, Radiolabeling and in Vivo Biological Evaluation of 99Mtc-Labeled MAG3-based Bisnitroimidazole Complexes As Tumor Hypoxia Markers

Synthesis and Biological Evaluation of Novel 99Mtcn-Labeled Bisnitroimidazole Complexes Containing Monoamine-Monoamide Dithiol As Potential Tumor Hypoxia Markers

Preparation and bioevaluation of a novel 99m Tc-labelled propylene amine oxime (PnAO) containing two 4-methyl-2-nitroimidazole groups as a promising tumor hypoxia imaging agent

Preparation and Bioevaluation of a Novel 99Mtc-Labelled Propylene Amine Oxime (pnao) Containing Two 4-Methyl-2-nitroimidazole Groups As a Promising Tumor Hypoxia Imaging Agent

Development of (99m)Tc-N4-NIM for molecular imaging of tumor hypoxia

Preparation and Biological Evaluation of 99Mtc-N4ipa for Single Photon Emission Computerized Tomography Imaging of Hypoxia in Mouse Tumor

In Vitro and in Vivo Evaluation of A Technetium-99m-Labeled 4-Nitroimidazole As A Tracer for Detection of Tumor Hypoxia

In vitro and in vivo evaluation of technetium‐99m‐labeled propylene amine oxime complexes containing nitroimidazole and nitrotriazole groups as hypoxia markers

Synthesis and preliminary biological evaluation of the 99mTc labeled nitrobenzoimidazole and nitrotriazole as tumor hypoxia markers.

Synthesis And Biodistribution Of Novel Tc-99m Labeled 4-Nitroimidazole Dithiocarbamate Complexes As Potential Agents To Target Tumor Hypoxia

Synthesis and Biodistribution of A New 99Mtc-Oxo Complex with Deoxyglucose Dithiocarbamate for Tumor Imaging

A thiourea‐bridged 99mTc(CO)3‐dipicolylamine‐2‐nitroimidazole complex for targeting tumor hypoxia: Utilizing metabolizable thiourea‐bridge to improve pharmacokinetics

Radio-Labelling and Micro-Pet Study of Cu-64 Labelled Pnao-1-(2-Nitroimidazole) for Hypoxia Imaging

Synthesis and Biodistribution of the 99m Tc Nitrido Complex with 2-(4-nitro-1h-imidazolyl)ethyl Dithiocarbamate (NIET)

Synthesis and evaluation of a novel 99mTcN(PNP)-complex with metronidazole isocyanide ligand as a marker for tumor hypoxia

Synthesis and Preliminary Evaluation of a Novel 18F-Labeled 2-Nitroimidazole Derivative for Hypoxia Imaging

Synthesis and Radiolabeling of (64)Cu-Labeled 2-Nitroimidazole Derivative (64)Cu-Bms2p2 for Hypoxia Imaging.

Synthesis and bioevaluation of the cyclopentadienyl tricarbonyl technetium-99m 2-nitroimidazole derivatives for tumor hypoxia imaging

Preliminary studies of 99mTc-BnAO and its analogues: synthesis, radiolabeling and in vitro cell uptake.

Improving Tumor/muscle and Tumor/blood Ratios of 99Mtc-Labeled Nitroimidazole Propylene Amine Oxime (pnao) Complexes with Ethylene Glycol Linkers.